Marketplace monitoring
FDA's latest Amazon warning letter is really about marketplace evidence
FDA's June 17, 2026 Amazon warning letter is a fresh reminder that marketplace listings can become source evidence.
Articles
FDA warning letter notes
Short articles based on public FDA source documents. Each article links to the warning letters it discusses.
Telehealth claims
What the June 2026 FDA telehealth warning-letter cluster shows
Public patient-facing pages, condition copy, and treatment funnels can become reviewable claims evidence.
OTC drug quality
What the PLZ Corp warning letter shows about component testing
Supplier documentation is not a substitute for a quality system that proves the result is reliable.
Sterile drug manufacturing
What the Sato warning letter shows about aseptic filling control
Repeated media-fill failures, ISO 5 airflow gaps, and weak stability testing made the Sato warning letter more than a routine drug CGMP item.
GLP-1 API traceability
What a GLP-1 API warning letter shows about supplier identity and traceability
FDA's Harbin Jixianglong Biotech warning letter turns one GLP-1 supply-chain question into a practical records check: who made it?
Supplements
FDA warning letter themes for supplement brands
Disease claims, blog posts, social links, and intended use issues in a recent dietary supplement warning letter.
Online claims
What FDA warning letters often say about website and marketing claims
How FDA reviewers used public web pages, social media, and online purchase paths in recent letters.
Digest
Weekly digest issue 1
Recent warning letters, Class I recall entries, and source-health notes from the May 13 monitor run.